Average ±SD progression-free survival with a SUVmax above 4.1 was 11.3±9.37 months, and a SUVmax below 4.1 was 19.6±12.05 months (p=0.001).22 Esra Arslanet al. showed the predictive potential of18F-FDG PET/CT and KRAS mutation in CRC, where the mean SUVmax with primary tumor was estimated to be 21.1±9.1 (range= 6.0–47.5) and tumor mean SUVmax with a KRAS mutation (24.0±9.0) was found to be significantly higher than those without a KRAS mutation (17.7±8.2) (p=0.001).23 Here, KRAS is linked to neoplasm.